Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial (NCT07286110) | Clinical Trial Compass
Not Yet RecruitingPhase 1
Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial
China66 participantsStarted 2025-12-30
Plain-language summary
Patients diagnosed with moyamoya vasculopathy by imaging and classified as having the Traditional Chinese Medicine (TCM) syndrome of liver-yang hyperactivity will be enrolled. On the basis of standardized Western medical management, participants will receive the standardized TCM herbal formula "Qiqi Shengmai Formula" (comprising Astragali Radix, Rehmanniae Radix Praeparata, Schisandrae Fructus, Bupleuri Radix, Paeoniae Radix Alba, and Notoginseng Radix). Structured follow-up will be conducted. By comparing endpoint indicators across different treatment regimens, the study aims to evaluate the efficacy of integrated TCM-Western medicine therapy for moyamoya vasculopathy and to generate evidence-based support for an integrated diagnostic and therapeutic model.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Imaging findings meeting the Western medical diagnostic criteria for moyamoya vasculopathy
✓. Age between 18 and 80 years
✓. The patient and family members are fully informed and voluntarily consent to participation, with the informed consent process conducted in accordance with GCP requirements
✓. Willingness to receive Traditional Chinese Medicine treatment
✓. Traditional Chinese Medicine syndrome differentiation consistent with liver-yang hyperactivity
Exclusion criteria
✕. Acute cerebrovascular events within the preceding 6 weeks
✕. Known allergy to contrast agents or to the investigational medication
✕. Presence of severe primary diseases involving the cardiac, pulmonary, hepatic, renal, endocrine, or hematopoietic systems
✕. Pregnant or breastfeeding women
What they're measuring
1
CT Perfusion
Timeframe: Baseline, at 3 months, 6 months, and 12 months after enrollment